PRINCE PHARM Business Summary

Prince Pharmaceutical Co., Ltd. (6935.TWO) is a Taiwan-based specialty pharmaceutical manufacturer that generates revenue through two primary business segments: Active Pharmaceutical Ingredients (APIs) and biochemical health foods. The company is a global leader in the synthesis of Vitamin B1 derivatives, including Fursultiamine, Thiamine Disulfide, and Bisbentiamine, alongside non-steroidal anti-inflammatory drugs (NSAIDs) such as Felbinac. Its business model leverages high-density manufacturing capabilities to provide Contract Development and Manufacturing Organization (CDMO) and Original Design Manufacturer (ODM) services for finished dosage forms, including tablets, capsules, and probiotic sachets. Prince Pharm serves a diverse international clientele across Japan, South Korea, and Europe, positioning itself as a critical supply chain partner for major Japanese pharmaceutical firms. In the competitive landscape, the company contends with regional players such as Bora Pharmaceuticals, Lotus Pharmaceutical, and Formosa Pharmaceuticals, distinguishing itself through its niche dominance in vitamin-based chemical synthesis and long-standing PIC/S GMP-certified production standards. The company’s leadership is spearheaded by Chairman and General Manager Hsieh Chan-Hung, who has overseen the firm’s strategic expansion and its 2023 listing on the Taipei Exchange. Founded in 1962, Prince Pharm has evolved from a traditional drug manufacturer into a technologically advanced chemical hub, a transition bolstered by the 2016 entry of the Nanpao Group as a significant strategic shareholder. The executive team, including Vice President Lin Kun-I and CFO Huang Shu-Fen, maintains a strong focus on regulatory compliance and R&D, ensuring adherence to international standards including cGMP, ISO, and HACCP. The board of directors reflects a blend of the founding family’s legacy and institutional expertise, with a pedigree defined by decades of technical collaboration with Japanese industry leaders. This established reputation for quality control has enabled the firm to maintain high-value partnerships and a stable market position within Taiwan’s biotechnology sector as of early 2026.